Exhibit 10.22



 Exhibit 10.22 
  
 CONFIDENTIAL TREATMENT REQUESTED: Certain portions of this document have been omitted pursuant to a request for confidential treatment and,
where applicable, have been marked with an asterisk (“[****]”) to denote where omissions have been made. The confidential material has been filed separately with the Securities and Exchange Commission. 
  
 LICENSE AGREEMENT 
  
 UNITED STATES OF AMERICA 
  
 AND 
  
 LUNA INNOVATIONS, INCORPORATED 
  
 NONEXCLUSIVE LICENSE AGREEMENT DN-982 







 TABLE OF CONTENTS 
  

			
		
	 PREAMBLE
	  	1
		
	 ARTICLE I Definitions
	  	2
		
	 ARTICLE II License Grant
	  	4
		
	 ARTICLE III Sublicenses
	  	5
		
	 ARTICLE IV Term of License
	  	5
		
	 ARTICLE V Practical Application
	  	5
		
	 ARTICLE VI United States Manufacture
	  	6
		
	 ARTICLE VII Royalty and Payment
	  	6
		
	 ARTICLE VIII Reports
	  	8
		
	 ARTICLE IX Audit Rights
	  	9
		
	 ARTICLE X Marking
	  	10
		
	 ARTICLE XI Use of the NASA Name
	  	10
		
	 ARTICLE XII Disclaimer of Warranties
	  	11
		
	 ARTICLE XIII Risk Allocation and Indemnification
	  	12
		
	 ARTICLE XIV Patent Validity
	  	12
		
	 ARTICLE XV Points of Contact
	  	13
		
	 ARTICLE XVI Notices
	  	14
		
	 ARTICLE XVII Dispute or Breach
	  	14
		
	 ARTICLE XVIII Termination or Modification
	  	15
		
	 ARTICLE XIX Assignment
	  	17
		
	 ARTICLE XX Governing Law
	  	18
		
	 ARTICLE XXI Independent Entities
	  	18

  

 -i- 









			
		
	 ARTICLE XXII Effect of Partial Invalidity
	  	18
		
	 ARTICLE XXIII Nonwaiver
	  	19
		
	 ARTICLE XXIV Entire Agreement
	  	19
		
	 ARTICLE XXV Article Headings
	  	19
		
	 ARTICLE XXVI Counterparts
	  	19
		
	 ARTICLE XXVII Acceptance
	  	20
		
	 Appendix
	  	 

  

 -ii- 








 LICENSE AGREEMENT 
  
 PREAMBLE 
  
 This License Agreement (“Agreement”) is entered into between the National Aeronautics and Space Administration (NASA), an agency of the United
States Government, hereinafter referred to as LICENSOR, having its headquarters at Washington, D.C., and Luna Innovations, Inc., a corporation of the Commonwealth of Virginia, having its principal place of business at 2851 Commerce Street SE,
Blacksburg, Virginia 26040, hereinafter referred to as LICENSEE, as of the date of execution of the last PARTY hereto. 
  
 WITNESSETH: 
  
 WHEREAS, under the authority of 35 U.S.C. § 200 et seq., the U.S. Department of Commerce has issued Patent Licensing Regulations
(37 CFR Part 404) specifying the terms and conditions upon which licenses may be granted for inventions assigned to LICENSOR; and 
  
 WHEREAS, LICENSOR is the assignee of U.S. Patent No. 5,798,521 for an invention entitled “Apparatus And Method For Measuring Strain In
Bragg Gratings,” which issued on August 25, 1998; and, U.S. Patent Application No. 09/535,659 for an invention entitled “Distributed Rayleigh Scatter Fiber Optic Strain Sensor”, which was filed on March 24, 2000; and
U.S. Patent Application No 09/535,661 for an invention entitled “Edge Triggered Apparatus And Method For Measuring Strain In Bragg Gratings”, which was filed on March 24, 2000; and U.S. Patent Application 09/648,529 for an invention
entitled “High Precision Solid State Wavelength Monitor”, which was filed on August 22, 2000; 
  
 WHEREAS, LICENSEE, in consideration of the grant of a license under U.S. Patent No. 5,798,521 and U.S. Patent Application Nos. 09/535,659,
09/535,661, and 09/648,529, will pay royalties, make all necessary capital investments, and achieve PRACTICAL APPLICATION of the inventions; and, 
  
 WHEREAS, LICENSOR has determined that the granting of a license to LICENSEE under U.S. Patent No. 5,798,521 and U.S. Patent Application Nos.
09/535,659, 09/535,661, and 09/648,529 will provide the necessary incentive for LICENSEE to achieve the desired early PRACTICAL APPLICATION of the invention and the granting of such license to LICENSEE will therefore be in the public interest;








 NOW, THEREFORE, in accordance with said Patent Licensing Regulations, and in consideration of the
foregoing and of the terms hereinafter contained in this Agreement, the LICENSOR and LICENSEE agree as set forth below: 
  
 ARTICLE I  
  
 Definitions 
  
 “ACCOUNTING PERIOD” shall mean the period for which minimum and running royalties are calculated. For this Agreement, the period is every twelve (12) months beginning on January 1st and ending on December 31st of
each calendar year. The first ACCOUNTING PERIOD for this Agreement commences on the LICENSE COMMENCEMENT DATE and ends on December 31, 2002. The last ACCOUNTING PERIOD for this Agreement shall end on the LICENSE EXPIRATION DATE. 
  
 “BREACH” shall mean (a) a violation or nonperformance by a
PARTY of a MATERIAL term, condition, covenant or warranty herein, or (b) a misrepresentation made hereunder or (c) a misrepresentation by LICENSEE to induce LICENSOR to enter into this Agreement (also see “MATERIAL”). 

 
 “BREACHING PARTY” shall mean the PARTY in BREACH, as used in
Article XVII. 
  
 “GROSS SALES” shall mean either the
total amount invoiced by or for LICENSEE and its SUBLICENSEE(S), and, in the event that some or all of the amount invoiced by LICENSEE and/or its SUBLICENSEE(S) is in the form of non-monetary remuneration, then the equivalent dollar value sum of
such remuneration, for all disposals, (sales, uses, including uses by LICENSEE and/or its SUBLICENSEES, leases, transfers, etc.) of ROYALTY-BASE PRODUCTS and ROYALTY-BASE SERVICES for consideration determined in, or as if in, an arm’s length
transaction. 
  
 “INSOLVENT” shall mean that LICENSEE
has either ceased to pay its debts (which may include failure to pay royalty payments under this Agreement) in the ordinary course of business or cannot pay its debts as they fall due or is insolvent within the meaning of the Federal Bankruptcy Code
(11 U.S.C. § 101 (31)). 
  
 “LICENSE COMMENCEMENT
DATE” shall mean the date that the last PARTY has executed this Agreement. 
  
 “LICENSE EXPIRATION DATE” shall mean the last day that this Agreement is in effect. 
  
 “LICENSE TERM” shall mean the period of time starting with the LICENSE COMMENCEMENT DATE and ending with the LICENSE EXPIRATION DATE.

  
 “LICENSED AREA” shall mean the United States, its
territories and possessions. 
  
 “LICENSED FIELD” shall
mean all fields of use. 
  
 “LICENSED INVENTION(S)”
shall mean the invention(s) defined by the claims of any LICENSED PATENT(S) or the invention(s) described in any LICENSED PATENT APPLICATION(S) before maturing into any LICENSED PATENT(S). 
  

 -2- 








 “LICENSED PATENT(S)” shall mean United States Patent No. 5,798,521 and any patents
maturing from any LICENSED PATENT APPLICATION, and shall include any corresponding: reissue patents and modifications of said LICENSED PATENT(S) by means of certificates of correction or reexamination certificates. 
  
 “LICENSED PATENT APPLICATION(S),” shall mean U.S. Patent
Application Serial Nos. 09/535,659, 09/535,661, and 09/648,529, and shall include any corresponding: continuation or divisional patent applications derived, directly or indirectly, from such patent applications, but specifically excluding any
continuation or divisional patent application containing new matter. 
  
 “MATERIAL,” with respect to a particular matter (e.g., a BREACH), shall mean that the matter is shown to effect adversely (a) the rights and benefits of the other PARTY under this Agreement; or (b) the ability of the
other PARTY to perform its obligations hereunder; and, in either case, to such a degree that a reasonable person in the management of his or her own affairs would be more likely than not to decline to enter into this Agreement in view of the matter
in question. 
  
 “NET SALES” shall mean GROSS SALES,
less allowances for returns and less (to the extent separately stated, and not charged to the customer or others, on the invoices): (1) regular trade and quantity discounts; (2) insurance and shipping charges from the point of origin;
(3) duties, tariffs, and other customs charges; and (4) sales, use, and similar taxes. In the case of a sale or other disposition of ROYALTY-BASE PRODUCTS and/or ROYALTY-BASE SERVICES which are transferred to a purchaser who does not deal
at arm’s length, or transferred or otherwise disposed of for other than monetary consideration (including allocations to LICENSEE’S own beneficial use), NET SALES shall be calculated in accordance with Sub-Article 7.7 of this Agreement.

  
 “NONBREACHING PARTY” shall mean the PARTY not in
BREACH, as used in Article XVII. 
  
 “PARTY” shall mean
a party to this Agreement. 
  
 “PERSON” shall mean a
natural person; a corporation (for profit or not-for-profit); an association; a partnership (general or limited); a joint venture; a trust; a government or political department, subdivision, or agency; or any other entity. 
  
 “PRACTICAL APPLICATION” shall mean, with respect to the LICENSED
INVENTION(S), to reduce it to practice and to commercialize it, i.e., to manufacture it in the case of a composition or product, to practice it in the case of a process or method, or to operate it in the case of a machine or system; and, in each
case, under such conditions as to establish: (i) that a market for the LICENSED INVENTION(S) has been created, and to the extent practicable, that a market has been created in the United States; (ii) that it is being utilized;
(iii) that its benefits are, to the extent permitted by law or Government regulations, available to the public on reasonable terms; and (iv) that market demand, at least in the United States, shall be reasonably met. 
  
 “ROYALTY-BASE PRODUCTS” shall include: (i) the components of
an item sold, used, leased, transferred, or otherwise disposed of by LICENSEE or its SUBLICENSEE(S) that are covered by, included within, or made by the LICENSED INVENTION(S); and (ii) other 

  

 -3- 








 
components of the item not covered by or within the LICENSED INVENTION(S) that LICENSEE or its SUBLICENSEE(S) would not have sold, used, leased, transferred,
or otherwise disposed of but for the sale, use, lease, transfer, or other disposition of the LICENSED INVENTION(S). 
  
 “ROYALTY-BASE SERVICES” shall include any services sold, used, leased, rented, transferred, or otherwise disposed of by LICENSEE or its
SUBLICENSEE(S) or agents which use, employ, or are implemented by the practice of the LICENSED INVENTION(S) and for which consideration is due or received by LICENSEE. 
  
 “SUBLICENSEE” shall mean any PERSON who has the right, granted by LICENSEE, to make, have made, use, offer to
sell, sell, transfer, or dispose of the LICENSED INVENTION(S). 
  
 “THIRD PARTIES” shall mean PERSONS other than the LICENSOR and the LICENSEE. 
  
 ARTICLE II  
  
 License
Grant 
  
 2.1 LICENSOR hereby grants to LICENSEE a terminable,
royalty-bearing, nonexclusive license to practice, i.e., to make, have made, use, offer to sell, sell, transfer, or dispose of, the LICENSED INVENTION(S) as limited to the LICENSED AREA and as may be limited to a LICENSED FIELD OR EMBODIMENT(S), as
defined in ARTICLE I. 
  
 2.2 LICENSOR, upon request, will use
reasonable efforts to grant LICENSEE, in accordance with 37 CFR 404, a license to practice any inventions assigned to LICENSOR, without which license or licenses, the practice of the LICENSED INVENTION(S) would result in infringement. The grant of
said license or licenses shall be limited, however, to the extent necessary to practice the LICENSED INVENTION(S). There will be no such grant where said inventions are licensed exclusively. 
  
 2.3 Notwithstanding anything to the contrary in this Agreement, LICENSEE
shall take the license granted in this ARTICLE II subject to any outstanding licenses or other rights in THIRD PARTIES under agreements executed by LICENSOR prior to the LICENSE COMMENCEMENT DATE. 
  
 2.4 LICENSOR retains a nontransferable, irrevocable, paid-up license for any
Federal agency to practice and/or have practiced the LICENSED INVENTION(S), and/or any other inventions as provided in Section 2.2, throughout the world by or on behalf of the Government of the United States and/or on behalf of any foreign
government pursuant to any existing or future treaty or agreement with the United States. 
  

 -4- 








 ARTICLE III 
  
 Sublicenses 
  
 3.1 Upon written approval by LICENSOR, LICENSEE may grant a written, royalty-bearing sublicense under the license granted in ARTICLE II provided that it
submits to LICENSOR a written request, in advance, for permission to grant the sublicense, including with said request a copy of the proposed sublicense. The proposed sublicense shall refer to and be generally consistent with this Agreement and
shall include the rights reserved by LICENSOR under Section 2.4. The proposed sublicense shall include the condition that the sublicense shall automatically terminate upon the revocation or termination of this Agreement. 
  
 3.2 LICENSEE shall furnish LICENSOR with a copy of the sublicense, consistent
with the proposed sublicense approved by LICENSOR and executed by both LICENSEE and its SUBLICENSEE, within fifteen (15) days after the grant of the sublicense by LICENSEE. 
  
 3.3 LICENSEE shall submit to LICENSOR, for advance approval, any proposed modification of a sublicense. LICENSEE shall also
submit to LICENSOR a copy of the sublicense modification (either as an addendum or a new sublicense), consistent with the proposed sublicense modification and executed by both LICENSEE and its SUBLICENSEE, within fifteen (15) days after the
effective date of the sublicense modification. 
  
 3.4 The
granting of a sublicense by LICENSEE shall not operate to relieve LICENSEE from any of its obligations under this Agreement. 
  
 3.5 LICENSEE shall be responsible for and remit royalties based upon its SUBLICENSEE(S)’ activities as if said activities were its own. 

 
 ARTICLE IV 
  
 Term of License 
  
 4.1 Unless either PARTY terminates this Agreement in accordance with Article XVIII at an earlier date, the license granted in ARTICLE II shall have a
LICENSE TERM that is equal to the unexpired term of the last patent of the LICENSED PATENT(S) to be in effect. Except as may be expressly provided otherwise herein or agreed to in writing by LICENSOR, the license shall expire automatically at the
end of the LICENSE TERM without notice to LICENSEE. 
  
 ARTICLE V

  
 Practical Application 
  
 5.1 LICENSEE shall achieve PRACTICAL APPLICATION of the LICENSED INVENTION(S)
within [****] of the LICENSE COMMENCEMENT DATE and in accordance with the schedule set forth in the APPENDIX to this Agreement and incorporated into this Agreement. LICENSEE shall notify LICENSOR within thirty (30) days of achieving
PRACTICAL APPLICATION that PRACTICAL APPLICATION has been achieved. LICENSEE shall also provide evidence to verify the achievement. 
  

 -5- 








 5.2 LICENSEE, once PRACTICAL APPLICATION of the LICENSED INVENTION(S) is achieved, shall thereafter
maintain it throughout the LICENSE TERM. 
  
 ARTICLE VI 

 
 United States Manufacture 
  
 6.1 In achieving PRACTICAL APPLICATION of the LICENSED INVENTION(S), LICENSEE
agrees that any products embodying the LICENSED INVENTION(S) or produced through the use of the LICENSED INVENTION(S) shall be reduced to practice and manufactured substantially in the United States, in accordance with 35 U.S.C. 209(b). 

 
 6.2 LICENSEE shall make a bona fide attempt to use or sell the LICENSED
INVENTION(S) in the United States. 
  
 6.3 LICENSEE shall promptly
report to LICENSOR its discontinuance of making the benefits of the LICENSED INVENTION(S) available to the public. 
  
 6.4 Failure to comply with the terms of this ARTICLE shall be cause for unilateral modification or termination by LICENSOR of this Agreement in accordance
with ARTICLE XVIII. 
  
 ARTICLE VII 
  
 Royalty and Payment 
  
 7.1 In consideration of the license granted in ARTICLE II, LICENSEE shall
remit to LICENSOR a nonrefundable license fee in the amount of [****] upon the execution of this Agreement by LICENSEE. This license fee shall be remitted to LICENSOR within thirty (30) days after the LICENSE COMMENCEMENT DATE.

  
 7.2 LICENSEE agrees to pay LICENSOR a nonrefundable,
repeatable license fee in the amount of [****] upon each issuance of a patent maturing from the LICENSED PATENT APPLICATION(S). This nonrefundable, repeatable license fee shall not exceed a total of [****]. LICENSEE shall remit each
[****] payment within thirty (30) days after notice of the issuance of such patent is delivered. 
  
 7.3 LICENSEE agrees to pay LICENSOR a running royalty, based upon the NET SALES of ROYALTY-BASE PRODUCTS and ROYALTY-BASE SERVICES, in accordance with the
following schedule for each ACCOUNTING PERIOD: 
  
 For NET SALES
up to and including [****] of NET SALES; or 
  
 For NET
SALES up to and including [****] of NET SALES exceeding [****]; or 
  

 -6- 








 For NET SALES exceeding [****] of NET SALES exceeding [****]. 
  
 7.4 LICENSEE shall pay LICENSOR a minimum annual royalty according to the
following payment schedule: 
  

			
	 End of year 2003:
	  	[****]
	 End of year 2004:
	  	[****]
	 End of year 2005:
	  	[****]

  
 Starting with the beginning of year
2006 and continuing thereafter throughout the LICENSE TERM, LICENSEE agrees to pay LICENSOR a minimum guaranteed royalty of [****] for each ACCOUNTING PERIOD. 
  
 7.5 For any particular ACCOUNTING PERIOD, the running royalties specified in Section 7.3 shall be credited against the
minimum royalty specified in Section 7.4. 
  
 7.6 LICENSEE
shall pay LICENSOR the running royalty of Section 7.3 above for NET SALES of ROYALTY-BASE PRODUCTS and ROYALTY-BASE SERVICES of any and all SUBLICENSEES as if said activities were its own. In addition to the running royalties of
Section 7.3, LICENSEE shall pay LICENSOR [****] of any consideration received from a SUBLICENSEE, including but not limited to sublicense issue fees, in exchange for the initial grant of a sublicense by LICENSEE for the LICENSED
INVENTION. In the event LICENSEE shall receive non-monetary consideration, including but not limited to equity in a SUBLICENSEE, in exchange for granting a sublicense, then LICENSOR and LICENSEE shall negotiate, in good faith, the present market
value of such consideration at the time of execution of such sublicense and the terms of payment of any amount due to LICENSOR with respect to such valued amount. 
  
 7.7 LICENSEE agrees that in the event any ROYALTY-BASE PRODUCTS OR ROYALTY-BASE SERVICES shall be sold, transferred, or
disposed of to a THIRD PARTY for purposes of resale in a transaction that does not represent an arm’s length transaction, then the royalties to be paid under this Agreement for the ROYALTY-BASE PRODUCTS or ROYALTY-BASE SERVICES shall be based
upon the NET SALES of the ROYALTY-BASE PRODUCTS or ROYALTY-BASE SERVICES by such THIRD PARTY, rather than upon the NET SALES of the LICENSEE. Examples of transactions that do not reflect an arm’s length transaction includes sales, transfers or
disposals (1) to any type of organization or individual who owns a controlling interest in LICENSEE by stock ownership or otherwise; (2) to any type of organization in which LICENSEE shall own, directly or indirectly, a controlling
interest by stock ownership or otherwise; or (3) to any type of organization with which, or individual with whom, LICENSEE, its stockholders, or associated companies shall have any agreement, understanding, or arrangement (such as, among other
things, an option to purchase stock, an arrangement involving a division of profits, or special rebates or allowances) without which agreement, understanding, or arrangement, prices paid by such organization or individual for the ROYALTY-BASE
PRODUCTS and/or ROYALTY-BASE SERVICES would be higher than the NET SALES reported by LICENSEE, or if such agreement, understanding, or arrangement results in extending to such organization or individual lower prices for ROYALTY-BASE PRODUCTS and/or
ROYALTY-BASE SERVICES than those charged to outside concerns buying similar merchandise in similar amounts and under similar conditions. 
  

 -7- 








 7.8 Under this Agreement, ROYALTY-BASE PRODUCTS and ROYALTY-BASE SERVICES will be considered sold when
invoiced, when shipped, or upon receipt of payment, whichever occurs first. 
  
 7.9 Minimum royalties, running royalties, and the royalties required under Section 7.6 shall be paid within thirty (30) days of the end of each ACCOUNTING PERIOD. Royalties shall be paid by check,
denominated in United States dollars, and made payable to the National Aeronautics and Space Administration. The check shall be mailed to LICENSOR at the address set forth in ARTICLE XV of this Agreement concurrently with the report required in
ARTICLE VIII of this Agreement. LICENSOR’S acceptance of any royalty payment does not eliminate LICENSOR’S right to contest the accuracy of such payment in the future. 
  
 7.10 LICENSOR shall assess interest, penalties, and administrative costs in accordance with the Federal Claims Collections
Standards on all payments due LICENSOR which are not timely paid by LICENSEE. In addition to these charges, LICENSOR is authorized to charge to LICENSEE the costs of collection and any associated reasonable attorney fees. 
  
 ARTICLE VIII 
  
 Reports 
  
 8.1 LICENSEE shall submit to LICENSOR written reports within thirty (30) days of the end of every ACCOUNTING PERIOD whether or not royalties are due.
Each report shall be submitted concurrently with the royalties required by ARTICLE VII. To ensure that any proprietary information submitted by LICENSEE is protected to the fullest extent of the law, LICENSEE should mark with a proprietary notice,
any portions of the report that is considered proprietary to LICENSEE. 
  
 8.2 Each report shall include the following information: 
  
 (a) With reference to the schedule set forth in the Appendix to this Agreement, a narrative description of the steps being taken to reduce the LICENSED INVENTION(S) to practice. 
  
 (b) With reference to the schedule set forth in the Appendix to this Agreement, a narrative description of the steps being
taken to create a market demand for the LICENSED INVENTION(S), to commercialize the LICENSED INVENTION(S), and to meet market demand for the LICENSED INVENTION(S). 
  
 (c) A narrative description of the ROYAL-BASE PRODUCTS and ROYALTY-BASE SERVICES currently being offered for sale by
LICENSEE and its SUBLICENSEES. Copies of current sales brochures, promotional materials, and price lists shall be included with this description. 
  
 (d) A list of the geographic locations at which the LICENSED INVENTION(S) are being manufactured. 
  

 -8- 








 (e) The number and type of ROYALTY-BASE PRODUCTS and ROYALTY-BASE SERVICES sold or disposed of by
LICENSEE and its SUBLICENSEES. 
  
 (f) The number and type of
ROYALTY-BASE PRODUCTS and ROYALTY-BASE SERVICES sold or disposed of by each reseller of ROYALTY-BASE PRODUCTS and ROYALTY-BASE SERVICES under Section 7.7. 
  

(g) LICENSEE’S GROSS SALES. 
  
 (h) GROSS SALES for each SUBLICENSEE (if any). 
  
 (i) GROSS SALES for each reseller under Section 7.7. 
  
 (j) LICENSEE’S NET SALES. 
  
 (k) NET SALES for each SUBLICENSEE (if any). 
  
 (l) NET SALES for each reseller under Section 7.7. 
  
 (m) The amount of royalties due LICENSOR. 
  
 8.3 Each report shall include a certification by an officer of LICENSEE that the LICENSEE is complying with the terms and conditions of this Agreement and
that the responses to each part of Section 8.2 are accurate and complete. 
  
 8.4 LICENSEE shall, on an annual basis, submit to LICENSOR an audited balance sheet and an audited income statement. Internal audits are permissible, but LICENSOR reserves the right to require an independent audit and
additionally reserves the right to approve of the auditor. 
  
 8.5
A final report shall be submitted to LICENSOR by LICENSEE within thirty (30) days after the termination of this Agreement. 
  
 ARTICLE IX 
  
 Audit Rights 
  
 9.1 LICENSEE shall keep full, true, and accurate records for the purpose of LICENSOR verifying LICENSEE’S reports to LICENSOR under ARTICLE VIII, verifying LICENSEE’S royalty payments to LICENSOR under
ARTICLE VII, and for determining LICENSEE’S activities in general under the Agreement. These records shall include, but are not limited to, ledgers and journals of account, customer orders, invoices, shipping documents, inventory records,
computer records, purchase orders, and tax records. These records, as a whole, shall include information which will allow, at a minimum, identification of suppliers, customers, items sold or otherwise transferred, and/or services rendered, as well
as whether the LICENSEE is operating within the scope of its license. 
  

 -9- 








 9.2 The records described in Section 9.1 shall be available for audit by LICENSOR, or by an
authorized representative of LICENSOR, at all reasonable times for the LICENSE TERM and for three (3) calendar years thereafter. In addition, LICENSEE shall permit inspection by LICENSOR, or by an authorized representative of LICENSOR, of
LICENSEE’S assembly facilities and of LICENSEE’S inventory of ROYALTY-BASE PRODUCTS, including parts, works-in-progress, and finished goods, during any audit by LICENSOR. 
  
 9.3 If LICENSOR, as a result of an audit, discovers an underpayment of royalties, which exceeds [****], then LICENSEE
shall reimburse LICENSOR for the cost of the audit, including all related costs of performing the audit (e.g., travel, food, lodging, cost of professional services, etc.), in addition to any penalties assessed pursuant to Section 7.10.

  
 ARTICLE X 
  
 Marking 
  
 10.1 LICENSEE and all SUBLICENSEE(S) shall mark all ROYALTY-BASE PRODUCTS, or products incorporating ROYALTY-BASE PRODUCTS
or ROYALTY-BASE SERVICES, in accordance with the statutes of the United States relating to the marking of patented articles (see 35 U.S.C. § 287). Such marking shall be accomplished by fixing on the article or when, from the character of
the article, this cannot be done, by fixing to it, or to the package wherein one or more of the articles is contained, a label including the notation “Licensed from the National Aeronautics and Space Administration under U.S. Patent
No. 5,798,521 and (insert other appropriate patent numbers).” Such marking shall also be included into all literature and/or advertising materials describing the LICENSED INVENTION(S). 
  
 ARTICLE XI 
  
 Use of the NASA Name 
  
 11.1 Except as required by Section 10.1, LICENSEE may use the name of LICENSOR, or the acronym “NASA”, only in truthful statements
concerning its relationship with LICENSOR. The letters ‘NASA’ may be used in such truthful statements only if they are: 
  
 (a) used in their normal typed or printed form; 
  
 (b) the same size, color, and intensity as the rest of the words in a sentence; 
  
 (c) not used in their stylized version as they appear in the NASA logotype or NASA insignia; and 
  
 (d) not used to indicate that NASA endorses the LICENSEE’S products,
processes, etc. 
  
 11.2 Uses of the letters ‘NASA’,
other than those required by Section 10.1 or specified in Section 11.1, shall require the express written approval of LICENSOR. Approval by LICENSOR 

  

 -10- 








 
shall be based on applicable law (i.e., 42 U.S.C. §§ 2459b, 2472(a), and 2473(c)(l); and 14 CFR § 1221.100 et seq.) and NASA
policy governing the use of the letters ‘NASA’ and the words ‘National Aeronautics and Space Administration’ and shall not be unreasonably withheld. 
  
 11.3 LICENSEE agrees to make copies of its marketing literature available to LICENSOR so that LICENSOR can determine that
such use is in accordance with the terms of this ARTICLE. 
  
 ARTICLE XII 
  
 Disclaimer of Warranties

  
 12.1 ALL REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED,
OR STATUTORY, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, ARE EXCLUDED HEREUNDER. 
  
 12.2 In particular, nothing in this Agreement shall be construed as: 
  
 (a) A warranty or representation by LICENSOR as to the validity or scope of any LICENSED PATENT; or 
  
 (b) A warranty or representation that anything made, used, sold, or otherwise
disposed of under any license granted in this Agreement is or will be free from infringement of any type, including patent infringement, copyright infringement, and trademark infringement; or 
  
 (c) A requirement that LICENSOR shall file any patent application, secure any
patent, or maintain any patent in force, other than the LICENSED PATENT; or 
  
 (d) An obligation to bring or prosecute actions or suits against THIRD PARTIES for infringement; or 
  
 (e) An obligation to furnish any manufacturing or technical information; or, if any such information is supplied, a warranty or representation that such
information is accurate; or 
  
 (f) Conferring a right to use in
advertising, publicity or otherwise the name of any inventor of the LICENSED INVENTION(S) or the NASA name, seal, insignia, logotype or any other adaptation without the prior written consent of LICENSOR (except as otherwise provided in ARTICLE XI);
or 
  
 (g) Precluding the export from the United States of
ROYALTY-BASE PRODUCTS on which royalties shall have been paid as provided in ARTICLE VII, provided that the item can be exported under the export control laws of the United States; or 
  
 (h) Granting by implication, estoppel, or otherwise, any licenses or other rights under any other patent of LICENSOR or any
other PERSON in the United States or any foreign country; or 
  

 -11- 








 (i) Granting by implication, estoppel, or otherwise, any licenses or rights under patents or patent
applications of LICENSOR other than the LICENSED INVENTION(S), regardless of whether such other patents or patent applications are dominant, subordinate, or an improvement to the invention or inventions as claimed, of the LICENSED PATENT(S) or
LICENSED PATENT APPLICATION(S), nor to other applications that did not claim the invention. 
  
 (j) Conferring upon any PERSON (1) any immunity from or defenses under the antitrust laws, (2) any immunity from a charge of patent misuse, or (3) any immunity from the operation of Federal, State, or
other law. 
  
 ARTICLE XIII 
  
 Risk Allocation and Indemnification 
  
 13.1 LICENSOR makes no representation, extends no warranties of any kind,
either express or implied, and assumes no responsibility with respect to use, sales, or other disposition by LICENSEE or its vendees or other transferees of products incorporating or made by the use of (1) the LICENSED INVENTION(S) or
(2) information, if any, furnished under this Agreement. 
  
 13.2 LICENSEE shall indemnify LICENSOR, its officers and employees, and hold them harmless against all liabilities, demands, damages, expenses, or losses including, but not limited to, attorney’s fees, court costs, and the like,
arising (1) out of the use by LICENSEE or its transferees of the LICENSED INVENTION(S) or information furnished under this Agreement, or (2) out of any sale, use, or other disposition by LICENSEE or its transferees of products, processes,
or compositions, made by use of such inventions or information. 
  
 13.3 It shall be the sole responsibility of the LICENSEE to ensure that any and all embodiments of the LICENSED INVENTION(S) are safe under all circumstances. 
  
 13.4 Independent of, severable from, and to be enforced independently of any other enforceable or unenforceable provision of
this Agreement, other than as provided in Sections 13.1 and 13.2, or other than for infringement of one PARTY’S intellectual property rights by another PARTY, (including any engagement in licensable activities by licenses beyond the scope
of the license provided by this Agreement), neither PARTY will be liable to the other PARTY (nor to any THIRD PARTY claiming rights derived from the other PARTY’S rights) for incidental, consequential, special, punitive, or exemplary damages of
any kind, including lost profits, loss of business, or other economic damage, and further including injury to property, as a result of breach of any warranty or other term of this Agreement, regardless of whether the PARTY liable or allegedly liable
was advised, had reason to know, or in fact knew of the possibility thereof. 
  
 ARTICLE XIV 
  
 Patent Validity

  
 14.1 If, in any proceeding in which the validity,
infringement, or priority of invention of any claim of the LICENSED PATENT to LICENSEE is in issue, a judgement or decree is entered 

  

 -12- 








 
which becomes final (below referred to as a “final judgement”), the construction placed upon any such claim by such final judgement shall
thereafter be followed, not only as to such claim but as to all claims to which such construction applies, with respect to subsequently occurring acts. If such final judgement holds any claim invalid, LICENSEE shall be relieved prospectively
(1) from including in its reports ROYALTY-BASE PRODUCTS and ROYALTY-BASE SERVICES sold or otherwise disposed of covered only by such claim or any broader claim to which such final judgement is applicable, and (2) from the performance of
those other acts which may be required by this Agreement only because of any such claim. However, if there are two or more conflicting final judgements with respect to the same claim based on the same grounds or where the same issues were raised,
the decision of the higher tribunal shall be followed, but if the tribunals be of equal dignity, then the decision more favorable to the claim shall be followed. In the event of conflicting irrevocable judgments of the Supreme Court of the United
States, the latest shall control. 
  
 14.2 In the event
evidentiary material comes to the attention of the LICENSEE after the LICENSEE’S execution of this Agreement which, in the judgement of the LICENSEE, bears on the validity or scope of any LICENSED PATENT, the LICENSOR will in good faith discuss
with the LICENSEE whether such evidentiary material so affects the validity or scope of the LICENSED PATENT to which it is asserted to apply that the terms of the Agreement in respect to such LICENSED PATENT should be modified. 
  
 14.3 The LICENSEE, after the LICENSE COMMENCEMENT DATE, may assert the
invalidity of any claim in any LICENSED PATENT, if coupled with or followed by: 
  
 (a) Withholding, or notice of intention to withhold, or denial of obligation to pay, royalties otherwise payable under this Agreement in respect to the LICENSEE’S operations under such claim; or 
  
 (b) Initiation or participation in a suit challenging or denying the validity
of such claim in reference to LICENSEE’S operations under this Agreement, that may, at the option of the LICENSOR, be conclusively presumed to constitute LICENSEE’S termination, as of the earliest provable date of such withholding, notice,
denial, initiation, or participation, of its Agreement including its obligation for payment of royalties due from the date of the termination. 
  
 ARTICLE XV 
  
 Points of Contact 
  
 15.1 The following individuals are designated as the points of contact for their respective PARTY. These points of contact are the principal representatives of the PARTIES involved in the performance of this
Agreement. 
  

			
	 LICENSOR

	  	 LICENSEE


	 NASA Langley Research Center
	  	Luna Innovations, Inc.
	 Patent Counsel Office
	  	Kent A. Murphy, President
	 Mail Stop 212, 3 Langley Blvd.
	  	2851 Commerce Street SE
	 Bldg. 1229, Room 14
	  	Blacksburg, VA 24060
	 Hampton, Virginia 23681-2199
	  	 
		
	 Telephone No.: [****]
	  	Telephone No.: [****]
	 Facsimile No.: [****]
	  	Facsimile No.: [****]

  

 -13- 








 ARTICLE XVI 
  
 Notices 
  
 16.1 Notices hereunder will be delivered and effective as follows: 
  
 (a) Every notice required or contemplated by this Agreement to be given either PARTY may be delivered in person or may be
sent by courier, express mail, telex, telegraph or postage prepaid certified or registered mail (or its equivalent under the laws of the country where mailed), addressed to the PARTY for whom it is intended, at the address specified in ARTICLE XV.
Either PARTY may change its address for notice by giving notice to the other PARTY of the change. 
  
 (b) Any written notice will be effective no earlier than the date delivered. 
  
 (c) Unless otherwise provided in this Agreement, notice by courier, or by express, certified, or registered mail, will be
deemed delivered on the date it is officially recorded as delivered by return receipt or the equivalent, and in the absence of such record as to delivery, it will be rebuttably presumed to have been delivered on the fifth business day after it was
deposited, first-class postage prepaid, in the mails. 
  
 (d)
Notice by telex or telegraph will be deemed delivered at the time it is recorded by the carrier in the ordinary course of business as having been delivered, but in any event no later than one business day after dispatch. 
  
 (e) Notice delivered in person or not given in writing will be deemed
delivered only if acknowledged in writing by a duly authorized officer of the PARTY to whom it was given. 
  
 (f) As used in this Article, a reference to a particular date means the date itself, if a business day, otherwise the first business day after the date.

  
 ARTICLE XVII 
  
 Dispute or Breach 
  
 17.1 All disputes concerning the interpretation or application of this
Agreement shall be discussed mutually between the PARTIES. Any disputes which are not disposed of by mutual Agreement shall be decided by the NASA Associate General Counsel (Intellectual Property), or designee, who shall reduce the decision to
writing and mail or otherwise deliver a copy of such 

  

 -14- 








 
decision to LICENSEE. LICENSEE shall have thirty (30) days after delivery of such copy of the decision to rebut such decision in accordance with the
procedures set forth in Article 18.8. 
  
 17.2 In the event of a
BREACH of any provision of this Agreement, the NONBREACHING PARTY shall give the BREACHING PARTY notice describing the BREACH and stating that the BREACHING PARTY has thirty (30) days after delivery of the notice of the BREACH to cure the
BREACH or show cause why the Agreement should not be terminated in accordance with Article 18.8. 
  
 17.3 If a provision of this Agreement sets forth a cure period for the BREACH in question other than thirty (30) days, then that provision shall take
precedence over the cure period set forth in Article 17.2. 
  
 17.4 No cure period is required, except as may be otherwise provided in this Agreement, if: 
  
 (a) this Agreement sets forth specific deadline dates for the obligation allegedly breached; or 
  
 (b) this Agreement otherwise states that no cure period is required in
connection with the termination in question. 
  
 17.5 The
BREACHING PARTY will be deemed to have cured such BREACH if within the cure period it takes steps reasonably adequate to alleviate any damage to the NONBREACHING PARTY resulting from the BREACH and to prevent a similar future BREACH. 
  
 ARTICLE XVIII 
  
 Termination or Modification 
  

18.1 The PARTIES may terminate or modify this Agreement by mutual consent upon such terms as they may agree in writing. 
  
 18.2 Either PARTY may terminate this Agreement by failing to extend the
LICENSE TERM, if an extension is provided for in Section 4.1. 
  
 18.3 Either PARTY may terminate this Agreement upon the discovery by one PARTY of any intentional MATERIAL false statement or misrepresentation made or submitted by the other PARTY which BREACHES any obligation under the terms of this
Agreement or upon the discovery by one PARTY that the other PARTY has committed a MATERIAL BREACH of a provision of the Agreement. 
  
 18.4 LICENSEE may prospectively terminate this Agreement upon ninety (90) days written notice to LICENSOR. 
  

 -15- 








 18.5 This Agreement may be terminated by LICENSOR if: 
  
 (a) LICENSOR determines that LICENSEE has failed or will fail to achieve or
maintain PRACTICAL APPLICATION of the LICENSED INVENTION(S) as provided by ARTICLE V. 
  
 (b) LICENSOR determines that LICENSEE has failed or will fail either to reduce to practice or to substantially manufacture the LICENSED INVENTION(S) in the United States as provided by Section 6.1 
  
 (c) LICENSOR determines that LICENSEE has failed or will fail to meet market
demand for the LICENSED INVENTION(S). 
  
 (d) LICENSEE fails to
pay royalties or submit reports as provided by ARTICLES VII and VIII. 
  
 (e) LICENSOR determines that such action is necessary to meet the requirements for public use specified by Federal regulations issued after the date of the license and such requirements are not reasonably satisfied by
LICENSEE. 
  
 (f) LICENSEE commits a MATERIAL BREACH of a covenant
contained in this Agreement. 
  
 18.6 LICENSOR may terminate this
Agreement if LICENSEE becomes “INSOLVENT.” LICENSEE must notify LICENSOR within thirty (30) days after becoming INSOLVENT. LICENSEE’S failure to conform to this requirement shall be deemed a MATERIAL, incurable BREACH.

  
 18.7 LICENSEE must promptly inform LICENSOR of its intention
to file a voluntary petition in bankruptcy or of another’s communicated intention to file an involuntary petition in bankruptcy. LICENSOR may terminate this Agreement upon receiving notice of intention to file. LICENSEE’s filing without
conforming to this requirement shall be deemed a MATERIAL, pre-petition incurable BREACH. 
  
 18.8 Before LICENSOR unilaterally modifies or terminates this Agreement for any cause, LICENSOR will deliver to LICENSEE and all SUBLICENSEES of record a written notice stating LICENSOR’S intention to modify or
terminate the Agreement and the reasons therefor. LICENSEE will be allowed thirty (30) days after such notice to remedy any BREACH of the Agreement or show cause why the Agreement should not be unilaterally modified or terminated. A response to
a notice of modification or termination, or to a copy of a dispute decision as rendered in accordance with Article 17.1, should be addressed to the General Counsel, National Aeronautics and Space Administration, Washington, DC 20546. The General
Counsel will render a determination, based on the LICENSEE’S response, within a reasonable time. Absent any response from LICENSEE to the notice regarding the modification, termination and/or dispute decision, the decision by the Associate
General Counsel (Intellectual Property) will be final, or as applicable, the Agreement will be unilaterally modified or will terminate, effective thirty-one (31) days from the delivery of the notice of the modification, the termination or the
dispute decision, with no right to appeal under Section 18.9. 
  

 -16- 








 18.9 LICENSEE may appeal in writing to the NASA Administrator, any determination rendered by the General
Counsel in accordance with Section 18.8, within thirty (30) days of notice of such determination. The notice of appeal and all supporting documentation should be addressed to the Administrator, National Aeronautics and Space
Administration, Washington, DC 20546. LICENSEE shall be afforded an opportunity to be heard and to offer evidence in support of its appeal. The decision on the appeal shall be made by the NASA Administrator or designee, which shall be the final
agency decision from which there will be no further right of administrative appeal. Nothing in this Article shall be interpreted as precluding actions at law. 
  

18.10 If no action is taken under Section 18.9, then the determination to modify or terminate this Agreement shall become final within thirty-one
(31) days after delivery of the determination rendered by the General Counsel in accordance with Section 18.8. 
  
 18.11 All royalties and reports due up to and including the date of termination of this Agreement are due within thirty (30) days of the date of
termination. 
  
 18.12 The word “termination” and
cognate words, such as “term” and “terminate”, used in this ARTICLE XVIII are to be read, except where the contrary is specifically indicated, as omitting from their effect the following rights and obligations, all of which
survive any termination to the degree necessary to permit their complete fulfillment or discharge: 
  
 (a) LICENSEE’S obligation to supply a final report as specified in Section 8.5 or ARTICLE VIII of this Agreement. 
  
 (b) LICENSOR’S right to receive or recover and LICENSEE’S
obligation to pay royalties accrued or accruable for payment at the time of any termination. 
  
 (c) LICENSEE’S obligation to maintain records and LICENSOR’S right to conduct a final audit in accordance with ARTICLE IX of this Agreement. 
  
 (d) Any cause of action or claim of LICENSOR accrued or to accrue, because of any BREACH or default by LICENSEE. 

 
 (e) Licenses, releases, and agreements of nonassertion running in favor of
customers or transferees of LICENSEE in respect to products sold or transferred by LICENSEE before any termination and on which royalties shall have been paid as provided in ARTICLE VII of this Agreement. 
  
 ARTICLE XIX  
  
 Assignment 
  
 19.1 Upon written approval by LICENSOR, LICENSEE may assign this Agreement
provided that LICENSEE submits to LICENSOR, in advance, a written request for permission to grant the assignment, information that NASA considers necessary to evaluate the proposed assignment, and a copy of the proposed assignment. If LICENSOR
approves the assignment as 

  

 -17- 








 
being consistent with the U.S. Government’s interests, the PARTIES and the assignee will be required to execute a novation Agreement. At a minimum, the
novation Agreement will provide that LICENSEE waives all rights under the license, the assignee assumes all obligations under the Agreement and that LICENSOR recognizes the assignee as the successor in interest to the Agreement. 
  
 ARTICLE XX  
  
 Governing Law 
  
 20.1 This Agreement will be interpreted and enforced in accordance with
United States federal law. 
  
 ARTICLE XXI 
  
 Independent Entities 
  
 21.1 The Parties are separate and independent entities. Except as may be
expressly and unambiguously provided in this Agreement, no partnership or joint venture is intended to be created by this Agreement, nor any principal-agent or employer-employee relationship. 
  
 21.2 Except to the extent expressly provided in this Agreement, neither PARTY
has, and neither PARTY shall attempt to assert, the authority to make commitments for or to bind the other PARTY to any obligation. 
  
 ARTICLE XXII 
  
 Effect of Partial Invalidity 
  
 22.1 If any one of more of the provisions of this Agreement should be ruled wholly or partly invalid or unenforceable by a court or other government body of competent jurisdiction, and as long as the fundamental
objectives of the Agreement can be carried out, then: 
  
 (a) the
validity and enforceability of all provisions of this Agreement not ruled to be invalid or unenforceable will be unaffected; 
  
 (b) the provision(s) held wholly or partly invalid or unenforceable will be deemed to be amended, and the court or other government body is authorized to
reform the provision(s), to the minimum extent necessary to render them valid and enforceable in conformity with the PARTIES’ intent as manifested herein; and 
  
 (c) if the ruling, and/or the controlling principle of law or equity leading to the ruling, is subsequently overruled,
modified, or amended by legislative, judicial, or administrative action, then the provision(s) in question, as originally set forth in this Agreement, will be deemed to be valid and enforceable to the maximum extent permitted by the new controlling
principle of law or equity. 
  

 -18- 








 ARTICLE XXIII 
  
 Nonwaiver 
  
 23.1 The failure of either PARTY at any time to require performance by the other PARTY of any provisions of this Agreement shall in no way affect the
right of such PARTY to require future performance of that provision. Any waiver by either PARTY of any BREACH of any provision of this Agreement shall not be construed as a waiver of any continuing or succeeding BREACH of such provision, a waiver of
the provision itself, or a waiver of any right under this Agreement. 
  
 ARTICLE XXIV 
  
 Entire Agreement 
  
 24.1 Except as may be expressly provided otherwise herein, this Agreement
constitutes the entire Agreement between the PARTIES concerning the subject matter thereof. No prior or contemporaneous representations, inducements, promises, or Agreements, oral or otherwise, between the PARTIES with reference thereto will be of
any force or effect. This Agreement may only be modified by written Agreement of the PARTIES. 
  
 ARTICLE XXV 
  
 Article
Headings 
  
 25.1 The ARTICLE headings contained in this
Agreement are for reference purposes only and shall not in any way control the meaning or interpretation of this Agreement. 
  
 ARTICLE XXVI 
  
 Counterparts 
  
 26.1 This Agreement may be executed in separate counterparts, each of which so executed and delivered shall constitute an original, but all such counterparts shall together constitute one and the same instrument. Any
such counterpart may comprise one or more duplicates or duplicate signature pages, any of which may be executed by less than all of the PARTIES, provided that each PARTY executes at least one such duplicate or duplicate signature page. The PARTIES
stipulate that a photostatic copy of an executed original will be admissible in evidence for all purposes in any proceeding as between the PARTIES. 
  

 -19- 








 ARTICLE XXVII 
  
 Acceptance 
  
 27.1 In witness whereof, each PARTY has caused this Agreement to be executed by its duly authorized representatives: 
  

									
	 LICENSOR:

	 	 	 	 LICENSEE:


			
	 National Aeronautics and
 Space Administration
	 	 	 	 Luna Innovations, Inc.

					
	 By:
	 	 /s/    Paul G. Pastorek

	 	 	 	 By:
	 	 /s/    Kent A. Murphy


					
	 	 	 Paul G. Pastorek
	 	 	 	 	 	 Kent A. Murphy

					
	 	 	 NASA General Counsel
	 	 	 	 	 	 President

			
	 Date: June 10, 2002
	 	 	 	 Date: May 14, 2002


  

 -20- 








 APPENDIX 
  

Luna Innovations Commercialization Plan Milestones 
  

			
	 Task Item

	  	TaskCompletion Date


		
	 1. [****]
	  	[****]
		
	 2. [****]
	  	[****]
		
	 3. [****]
	  	[****]
		
	 4. [****]
	  	[****]
		
	 5. [****]
	  	[****]








 CONFIDENTIAL TREATMENT REQUESTED: Certain portions of this document have been omitted pursuant to a request for
confidential treatment and, where applicable, have been marked with an asterisk (“[****]”) to denote where omissions have been made. The confidential material has been filed separately with the Securities and Exchange Commission.

  
 Modification No. l 
  
 NASA and Luna Innovations, Inc. entered into Nonexclusive License Agreement No. DN-982 on
June 10, 2002. By this Agreement, NASA and Luna Innovations, Inc. modify License Agreement DN-982 as follows: 
  

	1)	Article V – Practical Application, Section 5.2, is replaced by: 

  

	 	5.2 LICENSEE, once PRACTICAL APPLICATION of the LICENSED INVENTION(S) is achieved, shall thereafter maintain it throughout the LICENSE TERM, and shall achieve the milestones
provided in the APPENDIX to this Agreement. 

  

	2)	Article VII – Royalty and Payment, Section 7.3, is replaced by: 

  

	 	7.3 LICENSEE agrees to pay LICENSOR a running royalty of [****] of the NET SALES of ROYALTY-BASE PRODUCTS and ROYALTY-BASE SERVICES. 

  

	3)	Article VII – Royalty and Payment, Section 7.4, is replaced by: 

  

	 	7.4 LICENSEE shall pay LICENSOR a minimum annual royalty according to the following payment schedule: 

  

			
	 End of year 2003:
	  	[****]
		
	 End of year 2004:
	  	[****]
		
	 End of year 2005:
	  	[****]
		
	 End of year 2006:
	  	[****]
		
	 End of year 2007:
	  	[****]
		
	 End of year 2008:
	  	[****]
		
	 End of year 2009:
	  	[****]

  

	 	Starting with the beginning of year 2010 and continuing thereafter throughout the LICENSE TERM, LICENSEE agrees to pay LICENSOR a minimum guaranteed royalty of [****] for
each ACCOUNTING PERIOD. 









	4)	Appendix is replaced by: 

  
 APPENDIX 
  
 Luna Innovations Commercialization Plan Milestones 
  

			
	 Task Item

	  	 Task
 Completion Date


		
	 1.    [****]
	  	[****]
		
	 2.    [****]
	  	[****]
		
	 3.    [****]
	  	[****]
		
	 4.    [****]
	  	[****]
		
	 5.    [****]
	  	[****]
		
	 6.    [****]
	  	[****]
		
	 7.    [****]
	  	[****]
		
	 8.    [****]
	  	[****]

  

	5)	All other terms and conditions of Nonexclusive License Agreement No. DN-982 are hereby ratified and confirmed as remaining in full force and effect. 

  
 In witness thereof, each party has caused this Agreement to be executed by its duly
authorized representative. 
  

									
	National Aeronautics and Space Administration	 	 	 	Luna Innovations, Inc.
					
	 By:
	 	 /s/    Michael C. Wholley

	 	 	 	By:	 	 /s/    Kent A. Murphy


	 	 	         Michael C. Wholley
	 	 	 	 	 	         Kent A. Murphy

	 	 	         General Counsel
	 	 	 	 	 	         President

					
	 	 	 Date: January 23, 2006
	 	 	 	 	 	 Date: December 19, 2005


  

 -26-